Table of Content

Open Access iconOpen Access

ARTICLE

Late gadolinium enhancement and adverse outcomes in a contemporary cohort of adult survivors of tetralogy of Fallot

Richard J. Dobson1, Ify Mordi2, Mark H. Danton1, Niki L. Walker1, Hamish A. Walker1, Nikolaos Tzemos2

1 Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Clydebank, Dunbartonshire, United Kingdom
2 British Heart Foundation Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

* Corresponding Author: Richard J. Dobson, Scottish Adult Congenital Cardiac Service, Golden Jubilee National Hospital, Beardmore Road, Clydebank, Dunbartonshire, G81 4DY, United Kingdom. Email: email

Congenital Heart Disease 2017, 12(1), 58-66.

Abstract

Objective: Myocardial fibrosis has been associated with poorer outcomes in tetralogy of Fallot, however only a handful of studies have assessed its significance in the current era. Our aim was to quantify the amount of late gadolinium enhancement in both the LV and RV in a contemporary cohort of adults with surgically repaired tetralogy of Fallot, and assess the relationship with adverse clinical outcomes.
Design: Single centre cohort study
Setting: National tertiary referral center
Patients: One hundred fourteen patients with surgically repaired tetralogy of Fallot with median age 29.5 years (range 17.5-64.2). Prospective follow-up for mean 2.4 years (SD 1.29).
Interventions: Cardiovascular magnetic resonance was performed, and late gadolinium enhancement mass was estimated for the LV using the 5-SD remote myocardium method, and for the RV using a segmental scoring system. Cohort characterization was determined through the use of a computerized database.
Outcome measures: Survival analysis from time of scan to first adverse event, defined as an episode of atrial arrhythmia, sustained ventricular arrhythmia, hospitalization with heart failure, or implantable cardioverter-defibrillator insertion.
Results: Eleven patients experienced an adverse outcome in the follow-up period, although there were no deaths. LV late gadolinium enhancement was associated with adverse outcomes in a univariate model (P = .027). However, when adjusted for age at scan the significant variables included NYHA class (P = .006), peak oxygen uptake (P = .028), number of prior sternotomies (P = .044), and higher indexed RV and LV end diastolic volumes (P = .002 and P< .001), but not RV or LV late gadolinium enhancement.
Conclusions: Formal quantification of late gadolinium enhancement is not currently as helpful in ascertaining prognosis compared to other, more easily assessed parameters in a contemporary cohort of tetralogy of Fallot survivors, however assessment particularly of the LV holds promise for the future.

Keywords


Cite This Article

APA Style
Dobson, R.J., Mordi, I., Danton, M.H., Walker, N.L., Walker, H.A. et al. (2017). Late gadolinium enhancement and adverse outcomes in a contemporary cohort of adult survivors of tetralogy of fallot. Congenital Heart Disease, 12(1), 58-66.
Vancouver Style
Dobson RJ, Mordi I, Danton MH, Walker NL, Walker HA, Tzemos N. Late gadolinium enhancement and adverse outcomes in a contemporary cohort of adult survivors of tetralogy of fallot. Congeni Heart Dis. 2017;12(1):58-66
IEEE Style
R.J. Dobson, I. Mordi, M.H. Danton, N.L. Walker, H.A. Walker, and N. Tzemos "Late gadolinium enhancement and adverse outcomes in a contemporary cohort of adult survivors of tetralogy of Fallot," Congeni. Heart Dis., vol. 12, no. 1, pp. 58-66. 2017.



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1494

    View

  • 1123

    Download

  • 0

    Like

Share Link